The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr. may not be such a fan.

The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden administration said.

Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden on Tuesday, increasing access to the widely popular medications to millions of adults with obesity in the U.S., though the plan would likely face opposition under President-elect Donald Trump's second administration.

Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or Medicaid under a new rule the Biden administration proposed Tuesday morning.

For the 12% of adults in the U.S. now taking a weight-loss medication that targets the GLP-1 and/or GIP hormones to restrict appetite or treat diabetes—think Ozempic, Wegovy, Mounjaro, and Zepbound—the season is even more complicated.

The Biden administration on Tuesday proposed requiring Medicare and Medicaid to cover weight loss drugs like Wegovy and Ozempic. Why it matters: The rule would expand access to the medications for millions of Americans struggling with obesity,

A row is brewing between the White House and Robert F Kennedy Jr after the Biden administration proposed making millions of Americans eligible for government-funded weight-loss drugs.

The Biden administration called for Medicare and Medicaid to cover popular drugs that help people lose weight but are not affordable for many Americans who might benefit from them. NBC News' Stephanie Gosk reports.